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Abstract
Introduction: Ligament and meniscal damage can cause joint disease. Arthritic joints contain increased amounts of
epidermal growth factor receptor (EGFR) protein, and polymorphisms in EGFR are associated with arthritis risk. The
role of endogenous EGFR regulation during joint disease due to ligament and meniscal trauma is unknown.
Mitogen-inducible gene 6 (MIG-6) can reduce EGFR phosphorylation and downstream signaling. We examined the
effect of EGFR modulation by MIG-6 on joint disease development after ligament and meniscus injury.
Methods: Knee ligament transection and meniscus removal were performed surgically on mice homozygous for a
global inactivating mutation in MIG-6 (Mig-6−/−) and in wild-type (WT) animals.
Results: Two weeks after surgery, Mig-6−/−mice had bone erosion as well as greater fibrous tissue area and serum
RANKL concentration than WT mice. Four weeks after surgery, Mig-6−/−mice had less cartilage and increased cell
proliferation relative to contralateral control and WT knees. Increased apoptotic cells and growth outside the
articulating region occurred in Mig-6−/−mice. Tibia trabecular bone mineral density (BMD) and the number of
trabeculae were lower in surgically treated knees relative to the respective control knees for both groups. BMD, as
well as trabecular thickness and number, were lower in surgically treated knees from Mig-6−/−mice relative to WT
surgically treated knees. Phosphorylated EGFR staining in surgically treated knees decreased for WT mice and
increased for Mig-6−/−mice. Fewer inflammatory cells were present in the knees of WT mice.
Conclusion: Mig-6−/−mice have rapid and increased joint damage after ligament and meniscal trauma. Mig-6
modification could lessen degenerative disease development after this type of injury.
Introduction
Degenerative joint disease is painful and debilitating for
millions of individuals. Such disease is typically classified
as osteoarthritis (OA) or rheumatoid arthritis (RA). OA
is characterized by progressive loss of articular cartilage,
formation of bony outgrowths (osteophytes) and loss of
mobility [1]. During OA, the extracellular matrix (ECM)
network of cartilage tissue degrades, water content
increases, the size of ECM molecules decreases, the
structure of the collagen network is damaged and chon-
drocytes attempt to compensate through increased
proliferation and metabolism [2]. OA chondrocytes pro-
liferate and cluster as well as increase the production of
both matrix proteins and matrix-degrading enzymes [3].
Decreased chondrocyte metabolism and an inability to
adequately repair and regenerate the damaged tissue
lead to complete loss of cartilage tissue, subchondral
bone fibrillation and cyst formation [2,4,5].
The results of work by other researchers also suggest
that ECM mutations and disruption, as well as alter-
ations in the mechanotransductory sensory feedback
loop, which translates extracellular information to the
cell to facilitate the secretion of ECM, may contribute to
OA pathogenesis [6,7]. Pathologic cellular and structural
changes in ligaments, the supporting musculature and
fibrocartilaginous structures such as the meniscus and
the synovium (that is, synovial lining hyperplasia, macro-
phage and lymphocyte infiltration, neoangiogenesis, and
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fibrosis) are also observed in OA [8]. RA is characterized
by the presence of an immune-mediated inflammatory
synovitis that can invade and destroy the ECMs of joint
cartilage and bone [9]. Currently, there is no preventa-
tive or regenerative therapy for degenerative joint disease
and in an effort to advance treatment, research has been
focused on identifying the cell signaling pathways in-
volved in arthritic disease development [3].
The epidermal growth factor receptor (EGFR) signal-
ing pathway plays important roles in postnatal somatic
growth, chondrocyte differentiation and bone meta-
bolism [10-14]. EGFR is a tyrosine kinase receptor
that binds to a family of epidermal growth factor (EGF)–
like ligands, including EGF, amphiregulin, transforming
growth factor α (TGFα), heparin-binding EGF (HB-
EGF), betacellulin (BTC) and epiregulin. Upon ligand
binding, EGFR activates intracellular signal transduction
pathways (including Ras/Raf/mitogen-activated protein
kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/
Akt) in a variety of cells, thus modulating proliferation,
survival, adhesion, migration and differentiation [11].
Mice with osteoblast-specific deletion of EGFR have a
low bone mass phenotype, whereas mice with high
EGFR activity have a high bone mass phenotype [13].
Inhibited EGFR signaling can alter endochondral ossifi-
cation in mice and rats, and EGFR global knockout
(KO) mice display increased chondrocyte hypertrophy
[14,15]. TGFα signaling controls endochondral ossifica-
tion during bone growth [16]. EGFR signaling is involved
in diseases that affect cartilage. In humans, there is a
significant increase in the risk of RA development with
the occurrence of the single-nucleotide polymorphism
rs17337023 in EGFR, and arthritic joints have increased
EGFR2 protein in the synovial fluid and membrane
[17,18]. Pharmacological inhibition of EGFR can reduce
the severity of collagen-induced RA in mice, and the in-
hibition of EGFR by adenovirus can reduce joint damage
in arthritic mice [19,20]. Increased TGFα and EGFR sig-
naling have also been shown in rat OA [21,22].
Little is known about the influence of endogenous
EGFR regulation on skeletal diseases. Exogenous bigly-
can can regulate the expression of EGFR in human
chondrocytes, and mitogen-inducible gene 6 (MIG-6)—
also known as Gene 33, ErbB receptor feedback inhibitor
1 (ERRFI1) and RALT—is a negative feedback regulator
of EGFR [23,24]. The MIG-6 protein is a nonkinase
scaffolding adaptor found in the cytosol. When tran-
scriptionally induced by EGF, MIG-6 can reduce EGFR
tyrosine phosphorylation and thus also reduce down-
stream extracellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase (JNK) and protein kinase B (Akt)
activation through direct interaction with the EGFR
family [24,25]. MIG-6 is an immediate early response
gene whose expression can be rapidly and robustly
induced under normal and pathological conditions by
hormones, growth factors and stress [24]. Reports of
downregulated MIG-6 expression in a rat surgical
meniscectomy OA knee model and spontaneous devel-
opment of an OA-like phenotype in 3-month-old mice
with a global Mig-6 KO inactivating mutation (Mig-6−/−)
suggest a role for MIG-6 in joint disease. The influence
of endogenous EGFR regulation on joint disease pro-
gression after trauma to ligaments and menisci has been
unexplored [26,27].
Ligament and meniscus injury can alter mechanical
loads placed on the joint and cause severe damage to the
osteochondral joint surface and underlying trabecular
bone, thus contributing to the onset and progression of
joint disease [28-30]. We used a ligament/meniscus tran-
section model in Mig-6−/−mice to investigate the en-
dogenous regulation of EGFR by MIG-6 and its effects
on cartilage and bone damage after severe trauma. The
identification of early signaling cascades and knowledge
of cell behavior after ligament and meniscus injury are
vital to developing therapies for subsequent arthritis de-
velopment and progression. Therefore, we examined the
early effects of ligament and meniscus injury on bone
and cartilage in Mig-6−/−and wild-type (WT) mice. We
hypothesized that global KO of Mig-6 in mice would in-
crease EGFR signaling and disrupt cartilage and sub-
chondral bone homeostasis, leading to severe damage to
the cartilage and subchondral bone after ligament and
meniscus injury. Furthermore, we sought to determine
whether untreated ligament and meniscus injury would
rapidly progress to severe degenerative joint disease in
Mig-6−/−mice.
Materials and methods
Ethical approval
The Van Andel Research Institute Institutional Animal
Care and Use Committee approved all experimental
procedures.
Generation of mice and surgical destabilization model
Mig-6−/−mice were generated as described previously
[26]. The percentage of Mig-6−/−mice alive at birth was
less than that of heterozygous and WT littermates (6%
of Mig-6−/−, 65% of Mig-6+/−and 29% of WT mice);
therefore, some Mig-6−/−sample groups were smaller
than the corresponding WT groups for experimental as-
says [31]. Transection of the cruciate and meniscotibial
ligaments, as well as meniscus removal, were performed
on the right knees of 4-week-old Mig-6−/−mice (n = 36)
and their 4-week-old WT littermates (n = 42) using an
adaptation of a previously described surgical method
[32].
Mice were anesthetized by intraperitoneal injection
of 0.3 ml/g tribromoethanol and received 0.1 ml of
ketoprofen. The right medial meniscotibial ligament was
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sectioned to destabilize the medial meniscus. The anter-
ior cruciate, posterior cruciate and lateral meniscotibial
ligaments were transected, and the medial and lateral
menisci were removed. The patellar tendon and collateral
ligaments were not transected. The incision was then
closed with sutures and stapled. The animals resumed
normal ambulation within 1 - 2 hours after surgery.
Mig-6−/−mice showed spontaneous joint space narrowing at
1.5 months of age and increased joint damage severity at
3 months of age. Therefore, surgery was performed prior
to spontaneous disease onset on 4-week-old mice. Mice
were killed either 2 or 4 weeks after surgery by CO2
inhalation for endpoint analyses to examine the
influence of injury prior to observation of significant
spontaneous disease. On the basis of the limited number
of Mig-6−/−mice per litter and the survival rate of
Mig-6−/−animals after surgery, we used the left knee
from each animal as an untouched contralateral control
to acquire the sample sizes we needed for the outcome
measures. Other investigators have found negligible
cartilage damage similar to WT age-matched controls in
the contralateral joints of mice subjected to surgical
destabilization [33].
In vivo X-ray and micro–computed tomography
WT (n = 3) and Mig-6−/− (n = 3) mice were anesthetized
with 2.5% isoflurane in oxygen and X-rayed every week
after surgery with a piXarray digital specimen radiog-
raphy system (Bioptics Faxitron, Tucson, AZ, USA).
Knees from WT mice (n = 10) and Mig-6−/−mice (n = 6)
were imaged after excision at 28 days after surgery using
a SKYSCAN 1172 micro-CT scanner (Bruker, Ettlingen,
Germany). Samples were immersed in phosphate-buffered
saline and scanned, and damage to the knee joint trabecu-
lar bone was analyzed according to established laboratory
protocols [34].
Histology
Knees from WT mice (n = 17) and Mig-6−/−mice (n = 14)
were fixed and decalcified. Paraffin-embedded sections
(5 μm) were taken from the center of the medial condyle
through the center of the lateral condyle. Sagittal sec-
tions were stained with hematoxylin and eosin and
Movat’s pentachrome according to standard laboratory
protocols in order to examine cartilage and subchondral
bone. Nine sections from each sample were used for
each stain. The greatest perpendicular distance of articu-
lar cartilage thickness was measured with ImageJ soft-
ware (US National Institutes of Health, Bethesda, MD,
USA). Three physicians blinded to the samples scored
histological sections according to the Osteoarthritis
Research Society International scoring scale [35]. The
lowest score of 0 on this scale corresponds to normal
tissue and the highest score of 6 corresponds to bone
remodeling and microfibrocartilaginous/osseous repair.
The three grades for each section were averaged, and the
data from each group of mice were combined.
EGFR signaling is important for osteoclastogenesis;
therefore, tartrate-resistant acid phosphatase (TRAP)
staining was performed with a kit obtained from Sigma-
Aldrich (St Louis, MO, USA) according to manufac-
turer’s instructions to detect osteoclasts [36]. A terminal
deoxynucleotidyl transferase deoxyuridine triphosphate
nick-end labeling (TUNEL) assay was performed accord-
ing to the manufacturer’s instructions to assess cellular
apoptosis (Promega, Madison, WI, USA). Immunohisto-
chemistry (IHC) analysis was performed with a VEC-
TASTAIN ABC Kit (Vector Laboratories, Burlingame,
CA, USA) for Ki67 (SB M3060 at 1:100 dilution), a
marker for cell proliferation. We also performed IHC on
sections for monocytes, neutrophils and macrophages
(prediluted ab75693; the immunogen for this product is
an affinity-purified monocyte membrane preparation)
according to the manufacturer’s instructions. IHC nega-
tive controls were incubated in blocking buffer instead
of primary antibody. Stains were imaged with a Nikon
Eclipse 55i microscope equipped with a Nikon Digital
Sight camera (Nikon Instruments, Melville, NY, USA).
The percentage of pixels that stained positive for Ki67,
as well as monocytes, neutrophils and macrophages, was
quantified using a Nuance system (Burlington, MA,
USA). Quantitative stain analysis was performed on sec-
tions taken from the same-depth regions of the knee
joints in WT and KO mouse control and surgically
treated knees. Immunofluorescence (IF) was performed
on sections for phospho-EGFR (1:800) and total EGFR
(1:50) according to the manufacturer’s instructions. IF
images were obtained using an EVOS system (Advanced
Microscopy Group, Bothell, WA, USA), and all anti-
bodies were purchased from Abcam (Cambridge, MA,
USA), Cell Signaling Technology (Beverly, MA, USA),
Spring Bioscience (Pleasanton, CA, USA) or EMD Milli-
pore (Billerica, MA, USA).
Quantitative RT-PCR
Knees from WT mice (n = 8) and Mig-6−/−mice (n = 7)
were dissected under RNase-free conditions and homog-
enized in 1 ml of TRIzol reagent (Life Technologies,
Carlsbad, CA, USA) with a Fast Prep-24 tissue and cell
homogenizer (MP Biomedicals, Solon, OH, USA). RNA
was chloroform-precipitated and extracted with an
RNeasy Mini Kit (QIAGEN, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. RNA concentra-
tion was calculated and integrity was analyzed using a
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA) and an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA), respect-
ively, and potential DNA contamination was removed by
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RNase-free DNase treatment (amplification grade DNa-
seI; Sigma-Aldrich). cDNA was made with a RevertAid
First Strand cDNA Synthesis Kit (Fermentas, Glen
Burnie, MD, USA) on 0.5 μg of RNA. Primers used for
markers of osteogenesis and chondrogenesis (Integrated
DNA Technologies, Coralville, IA, USA) were as follows:
sox9: 5′- GCAGACCAGTACCCGCATCT-3′ and 5′-CTC
GTTCAGCAGCCTCCAG-3′; aggrecan: 5′- AGGACCT
GGTAGTGCGAGTG-3′ and 5′-GCGTGTGGCGAAG
AA-3′; col2a1: 5′- AATGGGCAGAGGTATAAAGATAA
GGA-3′ and 5′-CATTCCCAGTGTCACACACACA-3′;
col10a1: 5′-TTCATCCCATACGCCATAAAG-3′ and
5′-AGCTGGGCCAATATCTCCTT-3′; col1a1: 5′-CCTG
AGTCAGCAGATTGAGAACA-3′ and 5′-CCAGTACTC
TCCGCTCTTCCA-3′, runx2: 5′-CTGCAAGAAGGCTC
TGGCGT-3′ and 5′-CGGTTGGTCTCGGTGGCTGG-3′;
opn: 5′-GGCATTGCCTCCTCCCTC-3′ and 5′-GCAGG
CTGTAAAGCTTCTCC-3′; osx: 5′-GCAACTGGCTAG
GTGGTGGTC-3′ and 5′-GCAAAGTCAGATGGGTAA
GTAGGC-3′; ocn-1: 5′-CTCTGCTGACCCTGGCTG
CG-3′ and 5′-TGAGGCTCCAAGGTAGCGCC-3′; ocn-2:
5′- TGACCTCACAGATGCCAAGCCCA-3′ and 5′-AGG
GCTCTGGCCACTTACCCA-3′; and 18 s: 5′-GTAACC
CGTTGAACCCCATT-3′ and 5′-CCATCCAATCGGTA
GTAGCG-3′.
Western blot analysis
Knees from WT mice (n = 14) and Mig-6−/−mice (n = 12)
were homogenized in 1 ml of radioimmunoprecipitation
assay lysis buffer (50 mM Tris–HCl, 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid, 1 mM ethylene
glycol tetraacetic acid, 2 mM sodium orthovanadate, 20
nM sodium pyrophosphate, 1% Triton X-100, 1% so-
dium deoxycholate, and 0.1% SDS) using a Fast Prep-24
tissue and cell homogenizer. Protein concentration
was determined by bicinchoninic acid assay (Thermo
Scientific, Rockford, IL, USA). Protein (40 μg) was loaded
into the lanes of a 4% to 20% Mini-PROTEAN TGX
Precast Gel (Bio-Rad Laboratories, Hercules, CA, USA)
and subjected to electrophoresis. Membranes were probed
for phospho-EGFR, phospho-p44/42 ERK (pERK), total
p44/42 ERK or β-tubulin.
Enzyme-linked immunosorbent assay
We measured receptor activator of the nuclear factor κB
ligand (RANKL) and osteoprotegerin (OPG), which play
important roles in the formation of active osteoclasts
and can inhibit the RANKL/RANK interaction, respect-
ively [37]. Blood (200 μl) was collected from the orbital
sinus of WT mice (n = 7) and Mig-6−/−mice (n = 5) be-
fore surgery (baseline) and 2 and 4 weeks after ligament
and meniscus injury according to established animal
protocols. Blood was incubated for 2 hours at 37°C and
spun down at 12,000 rpm for 10 minutes at 4°C, and
serum was collected. OPG and RANKL concentrations
were determined using enzyme-linked immunosorbent
assay (ELISA) kits from R&D Systems (Minneapolis,
MN, USA) according to the manufacturer’s instructions.
All samples were assayed in duplicate.
Statistical analysis
GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA) was used for statistical analysis. We con-
firmed normality of the data sets and used a two-sided
unpaired Student’s t-test with Welch’s correction for
quantitative RT-PCR data. Repeated-measures analysis
was used for ELISA data. Two-way analysis of variance
with Tukey’s test for multiple comparisons was used for
all other quantitative data. We conducted an F-test to
determine whether variances were significantly different
between data sets and performed log transformation on
data for which variances were significantly different.
P-values less than 0.05 were considered statistically
significant.
Results
Early and severe degeneration of the knee joint after
injury in Mig-6−/−mice
Two weeks after ligament and meniscal transections,
hyperplastic disorganized fibrous tissue formed in the
knee joint space of Mig-6−/−and WT mice. We observed
a significantly greater fibrous tissue area and greater stain-
ing for fibrin in surgically treated knees of Mig-6−/−mice
(P < 0.001) and WT mice (P < 0.05) relative to respective
control knees (Figure 1A and 1B) The area of fibrous tis-
sue in Mig-6−/−surgically treated knees was significantly
greater than that in WT control (P < 0.001) or surgically
treated knees (P < 0.05) (Figure 1A and 1B).
Four weeks after surgery, the hyperplastic fibrous tissue
region was significantly greater in the surgically treated
knees of Mig-6−/−mice (P < 0.001) and WT mice (P < 0.01)
than in the knees of respective control mice (Figure 1C
and 1D). Surgically treated knees of Mig-6−/−mice in-
cluded cartilaginous pockets in areas outside the articulat-
ing surface (Figure 1C). We also qualitatively observed
cartilage degradation in surgically treated knees from
Mig-6−/−mice and joint space narrowing in surgically
treated knees from WT animals (Figure 1D). The fibrous
tissue area was significantly greater for both knees from
Mig-6−/−mice relative to the respective knees from WTan-
imals (P < 0.0001) (Figure 1C and 1D).
Four weeks after surgery, joint morphology was quali-
tatively similar between male and female mice of each
genotype (Additional file 1: Figure S1A). Therefore, sam-
ples were pooled for all quantitative analyses. Articular
cartilage thickness was significantly lower in Mig-6−/−
(P < 0.001) and WT (P < 0.05) surgically treated knees rela-
tive to respective control knees (WT control = 0.265 ±
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0.023 mm, WT surgically treated = 0.187 ± 0.015 mm,
Mig-6−/−control = 0.236 ± 0.031 mm and Mig-6−/− = surgi-
cally treated = 0.100 ± 0.027 mm). Articular cartilage thick-
ness in surgically treated knees from Mig-6−/−mice was
significantly lower than that in WT surgically treated mice
(P < 0.05) and WT control mice knees (P < 0.0001). The
histological score, indicative of disease severity, increased
significantly with surgery for both Mig-6−/−mice (P < 0.01)
and WT mice (P < 0.01) and was significantly higher
for Mig-6−/−knees than for WT control knees (P < 0.05)
(WT control = 1.1 ± 0.3, WT surgically treated = 4.8 ± 0.3,
Mig-6−/−control = 2.4 ± 0.6 and Mig-6−/−surgically treated
= 5.3 ± 0.3).
Cell proliferation and apoptosis were affected by injury
and loss of Mig-6. There was a significant increase (P <
0.001) in the percentage of Ki-67-stained pixels, indicative
of cell proliferation, in Mig-6−/−surgically treated knees
relative contralateral control knees (Figure 2A). The per-
centage of proliferating cells was significantly greater (P <
0.05) in surgically treated knees from Mig-6−/−mice than
in surgically treated knees from WT animals (Figure 2A).
Mig-6−/−mice had a significant increase (P < 0.01) in the
area of the TUNEL staining in surgically treated knees
relative to control knees, but there was no difference be-
tween the genotypes (Figure 2B).
We observed differences in chondrogenic and osteo-
genic markers in knees from Mig-6−/−and WT mice. Of
chondrogenic and osteogenic markers in Mig-6−/−surgi-
cally treated knees (relative to control knees), Sox9,
Col10a1, Runx2, Opn and Ocn-2 were downregulated 5-,
1.8-, 1.9-, 2.1- and 2-fold, respectively, relative to con-
trols (Figure 2C). In WT mice, Col10a1, Col1a1 and
Ocn-2 were upregulated 1.9-, 2.8- and 1.7-fold, respect-
ively, and Opn was downregulated 2.3-fold (Figure 2C).
Relative Sox9 expression was significantly lower in
Mig-6−/−knees than in WT (P < 0.01). Expression of
Col10a1 (P < 0.01), Col1a1 (P < 0.05) and Ocn-2 (P <
0.01) was significantly lower as well (Figure 2C).
Changes in bone structure after injury and loss of Mig-6
Femoral condyle bone erosion was evident by X-ray
2 weeks after surgery in Mig-6−/−mice, and deterioration
Figure 1 Animals that were used for micro–computed tomography were also used for histological analysis. (A) Hematoxylin and eosin
(H&E)–stained sections of control and surgically treated knees from wild-type (WT) and inactivated mitogen-inducible gene 6 (Mig-6−/−) mice at 2 weeks
after surgery (original magnification, 4×). Boxed regions are shown at higher magnification (original magnification, 20×). (B) Pentachrome-stained
sagittal sections of control and surgically treated knees from WT and Mig-6−/−mice at the 2-week time point. The black arrows point to joint space
narrowing, the yellow arrows point to cartilage degradation and fibrous tissue is outlined in blue. Muscle is stained red, cartilage blue, fibrin bright red,
and reticular yellow. Fibrous tissue area was quantified using ImageJ software (data are mean ± SE). (C) H&E-stained sections of control and surgically
treated knees from WT and Mig-6−/−mice at 4 weeks (original magnification, 4×). Boxed regions are shown at higher magnification (original magnifica-
tion, 20×). (D) Pentachrome-stained sagittal sections of control and surgically treated knees from WT and Mig-6−/−mice at the 4-week time point. The
black arrow points to joint space narrowing. Yellow arrows point to cartilage degradation. Fibrous tissue within the joint space of Mig-6−/−surgically
treated knees is shown at 20× and 40× original magnification and was quantified using ImageJ software (mean ± SE).
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of the femoral subchondral bone increased in severity
qualitatively at 4 weeks (Figure 3A). Subchondral bone
damage was qualitatively observed in three-dimensional,
reconstructed micro-CT images of surgically treated
knees from Mig-6−/−mice at 4 weeks (Figure 3B). Rela-
tive to WT control knees, we observed differences in tra-
becular bone geometry in the distal femur and proximal
tibia of WT surgically treated knees and in knees from
Mig-6−/−mice (Figure 3C and 3D).
In surgically treated knees relative to control knees, tib-
ial trabecular bone density and the number of trabeculae
decreased significantly (P <0.05), but the separation dis-
tance between trabeculae increased significantly (P <
0.01), for Mig-6−/−mice (Table 1). The thickness of tra-
beculae in the distal femur (P < 0.05) and proximal tibia
(P < 0.01) were significantly higher in surgically treated
knees of Mig-6−/−mice than in control knees, and the
distal femur bone volume fraction (ratio of the seg-
mented bone volume to the total volume of the region
of interest) was significantly lower in WT surgically
treated knees than in control knees (P < 0.05) (Table 1).
In the proximal tibia of Mig-6−/−surgically treated knees,
Figure 2 Cartilage and subchondral bone cell analysis. (A) Ki67 stain (brown) of knee tissue from wild-type (WT) and inactivated mitogen-inducible
gene 6 (Mig-6−/−) mice at 4 weeks after surgery. Arrows point to stained cells and cartilage (c) and subchondral bone (b) are labeled. For WT mice,
osteoblasts are stained in the subchondral bone and chondrocytes are stained in the cartilage. For Mig-6−/−mice, osteoblasts are stained in the
subchondral bone, chondrocytes are stained in the control knee cartilage and both fibroblasts and chondrocytes are stained in the surgically treated
knee cartilage. (B) Terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick-end labeling (TUNEL) stain of WT andMig-6−/−tissues at 4 weeks
postsurgery. Apoptotic cells are stained green, and nuclei are stained blue. c = cartilage and b = subchondral bone. For WT mice, osteoblasts are stained in
the subchondral bone and chondrocytes are stained in the cartilage. For Mig-6−/−mice, osteoblasts are stained in the subchondral bone, chondrocytes are
stained in the control knee cartilage and both fibroblasts and chondrocytes are stained in the surgically treated knee cartilage. ImageJ software was used
to quantify the area of positive TUNEL staining (mean ± SE). (C) RT-PCR data for WT and Mig-6−/−surgically treated knees (relative to control knees) at
4 weeks after surgery, expressed as mean ± SE. **P< 0.01 between genotypes and *P< 0.05 between genotypes. The amplification of gene products was
determined by the incorporation of SYBR Green I Nucleic Acid Gel Stain (Life Technologies, Carlsbad, CA, USA) and normalized to 18 s using the 2ΔΔ−Ct
method. Col10a1: Collagen, type X, α1; Col1a1: Collagen, type I, α1; Col2a1: Collagen, type II, α1; Ocn-1: Osteocalcin variant 1; Ocn-2: Osteocalcin variant 2;
Opn: Osteopontin; Osx: Osterix; Runx2: Runt-related transcription factor 2.
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trabecular thickness (P < 0.001), trabecular BMD (P <
0.01) and number of trabeculae (P < 0.05) were signifi-
cantly lower than in the WT surgically treated knees
(Table 1). Femur trabecular thickness was significantly
higher in the surgically treated knees of Mig-6−/−mice
than in WT surgically treated knees (P < 0.001) (Table 1).
Both tibia trabecular BMD (P < 0.05) and the number of
femoral trabeculae (P < 0.01) were significantly lower in
control knees of Mig-6−/−mice than in WT control knees,
and the distance between trabeculae was significantly lar-
ger for control knees of Mig-6−/−mice than for WT con-
trol knees in this region (P < 0.05) (Table 1). The effect of
surgery on trabecular thickness within the tibia and
femur was significantly different between genotypes (P <
0.01 for interaction).
Increased inflammatory cells and osteoclasts in Mig-6−/−mice
Serum RANKL concentration was significantly greater
in Mig-6−/−mice 2 weeks after surgery relative to the
concentrations in Mig-6−/−mice at baseline and at 4 weeks
after surgery and relative to the concentration for WTani-
mals at 2 weeks after surgery (P < 0.05) (Figure 4A). The
effects of genotype on RANKL concentration over time
were significantly different (P < 0.05 for interaction). For
WT mice, OPG concentration was significantly lower
(P < 0.001) at 4 weeks after surgery relative to the con-
centrations at 2 weeks after surgery and at baseline
(Figure 4B). Serum OPG concentration was significantly
greater for Mig-6−/−mice at baseline (P < 0.001) and at
2 weeks after surgery (P < 0.001) and at 4 weeks after sur-
gery (P < 0.0001) relative to the concentrations for WT
animals (Figure 4B), but there were no significant differ-
ences in the RANKL/OPG ratios between genotypes or
time points (Additional file 1: Figure S1B).
We observed significantly greater TRAP-positive cells
normalized to tissue area in the subchondral bone of
surgically treated knees from Mig-6−/−mice at 2 weeks
relative to Mig-6−/−control knees (P < 0.01) and relative
Figure 3 Three-dimensional reconstruction images were created for use in qualitative analysis. Images were reconstructed using Mimics
software (Materialise, Plymouth, MI, USA). (A) X-rays of control and surgically treated knees from wild-type (WT) and inactivated mitogen-inducible
gene 6 (Mig-6−/−) mice 2 and 4 weeks after surgery. Arrows point to subchondral bone erosion. (B) Three-dimensional reconstructed isosurfaces
of knees from WT and Mig-6−/−mice at 4 weeks after surgery. Arrows point to erosion and fragments in the subchondral bone. (C) Transverse view
of three-dimensional reconstructed isosurfaces of trabecular bone from the distal femurs of WT and Mig-6−/−knees 4 weeks after surgery. (D)
Transverse view of three-dimensional reconstructed isosurfaces of trabecular bone from the proximal tibia of knees from WT and Mig-6−/−knees
4 weeks after surgery.
Joiner et al. Arthritis Research & Therapy 2014, 16:R81 Page 7 of 13
http://arthritis-research.com/content/16/2/R81
to knees from WT animals (P < 0.001) (Figure 4C). We
found significantly greater TRAP-positive cells in the
subchondral bone of control knees from Mig-6−/−mice
at 4 weeks relative to control knees from WT mice
(Figure 4D). We did not find monocytes, neutrophils or
macrophages in WT or Mig-6−/−mice 2 weeks after
surgery (data not shown). The percentage of stained
pixels for monocytes, neutrophils and macrophages was
significantly greater in control and surgically treated
knees of Mig-6−/−mice than in WT controls (P < 0.001
and P < 0.01, respectively) or WT surgically treated knees
(P < 0.01 and P < 0.01, respectively) (Figure 5A).
Differences in alteration of phosphorylated epidermal
growth factor receptor protein after injury
The area of phospho-EGFR staining was significantly
lower at 4 weeks in control knees from Mig-6−/−mice
relative to surgically treated knees (P < 0.01) (Figure 5B).
The area of phospho-EGFR staining was significantly
lower at 4 weeks in surgically treated knees from WT
mice relative to control knees (P < 0.0001) and also to
surgically treated knees from Mig-6−/−mice (P < 0.05)
(Figure 5B). The effect of surgery on phospho-EGFR
staining in WT and Mig-6−/−mice at 4 weeks was signifi-
cantly different (P < 0.0001 for interaction).
There were no significant differences in the area of
EGFR staining between control and surgically treated
knees from WT and Mig-6−/−mice at 4 weeks or between
genotypes (Figure 5C). Phospho-EGFR densitometry
was significantly lower at 4 weeks in surgically treated
knees from WT mice relative to control knees (P < 0.05)
and also to surgically treated knees from Mig-6−/−mice
(P < 0.0001) (Figure 5D). Phospho-EGFR densitometry
was significantly lower at 4 weeks in control knees from
Mig-6−/−mice relative to surgically treated knees (P <
0.0001) (Figure 5D). There were no significant differ-
ences in pERK densitometry or total ERK densitometry
between control and surgically treated knees from WT
and Mig-6−/−mice at 4 weeks or between genotypes
(Figure 5D and Additional file 2: Table S1). The phospho-
ERK densitometry normalized to total ERK densitometry
was significantly lower in control knees (P < 0.01) and
surgically treated knees (P < 0.0001) from WT mice rela-
tive to control knees from Mig-6−/−mice (Figure 5D).
Discussion
We found exacerbated and accelerated cartilage and sub-
chondral bone damage in young Mig-6−/−mice after liga-
ment and meniscal trauma, as well as increased EGFR
phosphorylation. Increased cell proliferation has been re-
ported in Mig-6−/−mice, and reduced proliferation has
been reported in cells overexpressing Mig-6 and treated
with hepatocyte growth factor [31,38]. We found no differ-
ences between genotypes in terms of control knee cell
proliferation, but we observed a greater number of prolif-
erating cells and staining for phospho-EGFR in surgically
treated knees from Mig-6−/−mice (relative to their control
knees and to surgically treated knees from WT mice),
which likely contributes to increased cell growth. Despite
increased proliferation, Sox9 gene expression was down-
regulated in Mig-6−/−surgically treated knees, which could
be due to reduced articular cartilage.
We did not detect consistent increases in phospho-
ERK, total ERK or phospho-EGFR protein levels for both
Table 1 Tibia and femur trabecular bone micro-CT dataa
Bone WT Mig-6−/−
Control Surgery Control Surgery
Tibia
Trabecular BMD (g/ml) 0.579 ± 0.010 0.528 ± 0.006b 0.524 ± 0.028c 0.459 ± 0.009b,d
Trabecular thickness (mm) 0.022 ± 0.000 0.022 ± 0.001 0.020 ± 0.001 0.021 ± 0.001e,f
Number of trabeculae 5.918 ± 0.280 5.437 ± 0.405b 4.395 ± 0.744 2.545 ± 0.187g,h
Separation distance between trabeculae (mm) 0.138 ± 0.012 0.139 ± 0.004 0.242 ± 0.044 0.289 ± 0.063e
BV/TV (%) 12.473 ± 0.483 13.042 ± 0.340 8.385 ± 1.780 10.670 ± 3.765
Femur
Trabecular BMD (g/ml) 0.590 ± 0.011 0.579 ± 0.015 0.551 ± 0.019 0.533 ± 0.022
Trabecular thickness (mm) 0.025 ± 0.001 0.023 ± 0.001 0.024 ± 0.002 0.031 ± 0.001b,f
Number of trabeculae 6.214 ± 0.632 4.866 ± 0.419 3.716 ± 0.093i 4.573 ± 0.545
Separation distance between trabeculae (mm) 0.124 ± 0.009 0.158 ± 0.023 0.225 ± 0.040c 0.190 ± 0.033
BV/TV (%) 16.502 ± 1.011 10.893 ± 1.069b 11.747 ± 2.764 14.499 ± 2.678
aBMD: Bone mineral density; BV/TV: Bone volume fraction (ratio of the segmented bone volume to the total volume of the region of interest); Mig-6−/−: Inactivated
mitogen-inducible gene 6; WT: Wild type. Animals that were X-rayed were also used for micro-CT analysis. Data are expressed as mean ± SE. bP < 0.05 between
control and surgery. cP < 0.05 between genotypes for control knees. dP < 0.01 between genotypes for surgically treated knees. eP < 0.01 between control and
surgery. fP < 0.001 between genotypes for surgically treated knees. gP < 0.001 between control and surgery. hP < 0.05 between genotypes for surgically treated
knees. iP < 0.01 between genotypes for control knees.
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knees from Mig-6−/−mice relative to WT, but these pro-
teins can be influenced by other pathways that balance
EGFR signaling. EGFR signaling is maintained by the
endocytic pathway, which is crucial for the spatial
localization of the EGF–EGFR complex needed to acti-
vate downstream effectors [39]. EGF binding can cause
the EGF–EGFR complex to internalize and traverse the
endocytic pathway, moving from clathrin-coated vesicles
through endosomes to lysosomes for degradation [39].
This process, though it was not examined in this study,
could sequester EGFR from downstream effectors in
addition to removing the receptor from the cell surface,
dephosphorylating the receptor or targeting the ligand–
receptor complex for degradation [39].
Investigators in several studies have highlighted the in-
fluence of Mig-6 and EGFR on apoptosis. Pharmaco-
logical compounds can induce apoptosis in lung and
breast cancer cells by inhibiting the EGFR pathway, and
recent work has demonstrated that Mig-6 actively senses
EGF deprivation to directly activate proapoptotic c-Abl
Figure 4 Mice used for micro-CT analysis were also used for enzyme-linked immunosorbent assay measurements. (A) Serum receptor
activator of nuclear factor κB ligand (RANKL) concentration for wild-type (WT) and inactivated mitogen-inducible gene 6 (Mig-6−/−) mice
expressed as mean ± SE. *P < 0.05. (B) Serum osteoprotegerin (OPG) concentration for WT and Mig-6−/−mice expressed as mean ± SE. ***P < 0.001
and ****P < 0.0001. (C) Arrows point to tartrate-resistant acid phosphatase (TRAP)-positive cells (pink) in the subchondral bone of knees from WT
and Mig-6−/−mice 2 weeks after surgery. The number of TRAP-stained cells was counted manually and normalized to the tissue area (mean ± SE).
(D) Arrows point to TRAP-positive cells (pink) in the subchondral bone of knees from WT and Mig-6−/−mice 4 weeks after surgery. The number of
TRAP-stained cells was counted manually and normalized to the tissue area (mean ± SE).
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in murine epithelial cells [40-42]. Mig-6 can trigger
apoptosis as well as exacerbate endoplasmic reticulum
stress-induced β-cell death [43]. Apoptosis inhibition
in MCF7 human breast cancer cells with exogenous over-
expression ofMig-6 has been shown, but increased cleaved
caspase 3 immunostaining in lungs from Mig-6−/−mice
has also been reported [31,44]. In our present study, we
observed an increase in apoptotic cells in the surgically
treated knees from Mig-6−/−mice relative to control
knees, which may be attributed to increased EGFR phos-
phorylation and also to damage in the articular cartilage
and underlying subchondral bone.
EGFR signaling has been linked to inflammation, but
limited data exist regarding the effect of Mig-6 on in-
flammation. Histological reports show staining for EGFR
in the bronchial epithelium, glands, smooth muscle cells
and basement membranes of chronically inflamed asth-
matic airways, and EGFR inhibition can reduce the num-
ber of inflammatory cells, as well as interleukin 4 and
interleukin 13 concentrations, in bronchoalveolar lavage
fluid [45,46]. EGFR inhibition can also reduce eosinophil
recruitment in the lungs as well as airway hyperrespon-
siveness. The concentrations of serum and joint EGF
and EGFR are significantly higher in RA patients than in
Figure 5 Inflammation and epidermal growth factor receptor analysis. (A) Sagittal sections of knees from wild-type (WT) and inactivated mitogen-
inducible gene 6 (Mig-6−/−) mice 4 weeks after surgery stained for monocytes, neutrophils and macrophages (brown). C: control knee and S: surgery
knee. (B) Phosphorylated epidermal growth factor receptor (phospho-EGFR) staining (red) of knees from WT and Mig-6−/−mice counterstained with
4′,6-diamidino-2-phenylindole (DAPI blue) (original magnification, 10×) 4 weeks after surgery. ImageJ software was used to quantify the area of
phospho-EGFR staining (mean ± SE). (C) Total EGFR staining (red) of knees from WT and Mig-6−/−mice counterstained with DAPI (blue) (original
magnification, 10×) 4 weeks after surgery. ImageJ software was used to quantify the area of total EGFR staining (mean ± SE). (D) Western blots from
control (C) and surgery (S) knees isolated from WT and Mig-6−/−mice probed for phospho-EGFR, phosphorylated extracellular signal-regulated kinase
(phospho-ERK), total ERK and β-tubulin. Densitometry (mean ± SE) was determined using ImageJ software. The positive (+C) and negative control (−C)
lysates were protein extracts from calvarial osteoblasts isolated from 3-day-old WT mice subjected to either 60 minutes of 2 Pa of fluid shear stress or
no mechanical stimulation. Gel lane numbers are written on some of the blots.
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healthy populations, and the thymuses of Mig-6−/−mice
are larger than normal size; however, significant num-
bers of inflammatory cells were not observed in previous
studies of Mig-6−/−joints [26,46]. Mig-6 can be transcrip-
tionally induced by hormones and growth factors as well
by stresses such as mechanical strain and impact [47,48].
In Mig-6−/−mice, we found increased numbers of in-
flammatory cells, which may occur naturally in younger
Mig-6−/−mice prior to observation of significant spon-
taneous disease and could also be a compensatory re-
sponse to the stresses placed on the surgically treated
knee joint by the altered mechanical environment in-
duced by ligament and meniscus injury [49].
Relative to WT animals, we observed some impair-
ment to trabecular bone in the control and surgically
treated knees of Mig-6−/−mice, which could reduce
the mechanical integrity of the knee joints [50]. There
was an increase in trabecular thickness with surgery in
Mig-6−/−mice, which may be a result of skeletal adapta-
tion and an attempt to compensate for joint damage
and/or increased EGFR phosphorylation [13]. There is
also evidence that EGFR signaling is involved in osteo-
clast formation and that it may have functional import-
ance for osteoclast differentiation and survival. Thus,
increased EGFR phosphorylation in surgically treated
knees of Mig-6−/−mice could contribute to the observed
subchondral bone resorption and increased RANKL [36].
It has been suggested that the impact of Mig-6 might
manifest only during dynamic processes such as devel-
opment or injury repair [31]. EGFR is activated in re-
sponse to a wounding event, and signaling pathways
downstream from EGFR are central in regulating distinct
stages of wound healing [51]. Together, the inactivation of
Mig-6 and increased EGFR phosphorylation in surgically
treated knees of mutant mice may increase inflammation
and thus apoptosis, leading to reduced articular cartilage
thickness. Reduced cartilage thickness in Mig-6−/−mice
could further increase the loads on the joint, causing
additional damage to the underlying subchondral bone.
Despite increased cell proliferation (perhaps in an en-
hanced attempt to repair damage), the joint integrity in
Mig-6−/−mice remains compromised because of undir-
ected cell growth. Therefore, Mig-6−/−mice develop rapid
and more severe cartilage and subchondral bone damage
after ligament and meniscus injury.
Four weeks after surgery, we observed joint space nar-
rowing in control knees from Mig-6−/−mice that was
comparable to that previously reported in 1.5-month-old
Mig-6−/−animals, but we did not observe joint space
narrowing in WT control knees and therefore attribute
this phenomenon to early-stage joint disease associated
with loss of function in Mig-6−/−animals. Fifty percent of
Mig-6−/−mice die before adolescence, likely because of im-
pairments in pulmonary development and vascularization
of the lungs [31]. The limited survival of adult
Mig-6−/−mice enabled us to study only early changes to
cartilage and subchondral bone after trauma to ligaments
and the meniscus in young mice. Several cell types are
found in the knee joint under normal and pathological
conditions. Synovial lining cells produce lubricin and hya-
luronic acid, which help to protect and maintain the integ-
rity of the cartilage surface [8]. Fibroblasts, macrophages
and lymphocytes participate in synovial hyperplasia and
inflammation, and osteoblasts, osteoclasts and chondro-
cytes, respectively, form and resorb bone and maintain
cartilage [3,8,52]. In our present study, we were able to ob-
serve the effect of inactivation of Mig-6 in all cell types in-
volved in joint maintenance after ligament and meniscal
damage, but we did not completely elucidate the exact
mechanism of action of Mig-6 in joints. Our study opens
the door for future work focused on dissecting the exact
mechanism of Mig-6 and EGFR signaling in joint damage
after ligament and meniscus injury.
Conclusion
Phospho-EGFR was lower in surgically treated knees
from WT mice relative to controls, and joint damage
was less severe in these animals relative to Mig-6−/−mice,
which conversely had increased phospho-EGFR in surgi-
cally treated knees relative to controls. There could be a
threshold of EGFR signaling required for maximum
therapeutic effect after trauma to the ligaments and me-
niscus, and attenuation of Mig-6 could be a strategic tool
for finely altering EGFR signaling and reducing cartilage
and subchondral bone damage after this type of injury.
Additional files
Additional file 1: Figure S1. (A) Pentachrome-stained sagittal sections
of control and surgically treated knees from male and female wild-type
(WT) and inactivated mitogen-inducible gene 6 (Mig-6−/−) mice 4 weeks
after surgery. Muscle (red), cartilage (blue), fibrin (bright red) and reticular
fibers (yellow) are shown. Original magnification, 4×. (B) Serum RANKL
(receptor activator of nuclear factor κB ligand) concentration normalized
to osteoprotegerin concentration for WT and Mig-6−/−mice expressed as
mean ± SE.
Additional file 2: Table S1. Western blot densitometry.
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